CD8+ Tsen populations were also not increased (30.7%) in another 72-year-old patient with breast cancer with bone metastases who had no previous treatment with cytotoxic agents and is currently treated with abemaciclib (Fig. 3b). Here, CD8A is linked to breast carcinoma.